Enliven Therapeutics Inc. (Nasdaq: ELVN), a Boulder clinical-stage precision oncology company, has enough cash on hand to fund operations into late 2026, the company disclosed this week, and through multiple milestones for two of its drug candidates.

Related Keywords

Sam Kintz , Nasdaq , Enliven Therapeutics Inc , Enliven Therapeutics ,